Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN), with dominated clinical phenotype of splenomegaly, constitutional symptoms, blood cell alterations, and potential to develop vascular complications.  Moreover, anaemia and thrombocytopenia are key characteristics in patients with MF.  However, the underlying causes are incompletely understood.  This symposium will be discussing the significant need and the burden of disease among patients with myelofibrosis who have anaemia and thrombocytopenia.  The current treatment options for myelofibrosis and their limitations in the management of anaemia and thrombocytopenia.  Besides, reviewing the clinical trial data from emerging treatments, with a focus on patients with myelofibrosis who have anaemia and thrombocytopenia.